The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

References

• Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
   PubMed Web of Science ®Google Scholar
• Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J Clin Rheumatol 2006;12:124-8
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008;62:115-26
   PubMed Web of Science ®Google Scholar
• Chandran A, Goldenberg D, Schaefer C, et al. Can fibromyalgia severity help us to better understand the patient: results from a cross-sectional survey in the United States? Journal of Pain 2010;11:S4
   Google Scholar
• Silverman S, Sadosky A, Evans C, et al. Toward characterization and definition of fibromyalgia severity. BMC Musculoskelet Disord 2010;11:66
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
   PubMed Web of Science ®Google Scholar
• Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-21
   PubMed Web of Science ®Google Scholar
• Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011;41:335-45
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95
   PubMed Web of Science ®Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66
   PubMed Web of Science ®Google Scholar
• Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin–a meta-analysis of randomized controlled trials. Pain 2009;145:69-81
   PubMed Web of Science ®Google Scholar
• Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta–analysis. J Clin Pharm Ther 2010;35:639-56
   PubMed Web of Science ®Google Scholar
• Kim L, Lipton S, Deodhar A. Pregabalin for fibromyalgia: some relief but no cure. Cleve Clin J Med 2009;76:255-61
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al. An International, randomized, double-blind, placebo-controlled, phase iii trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;CD007076
   Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33
   PubMed Web of Science ®Google Scholar
• Bennett RM, Bushmakin AG, Cappelleri JC, et al. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009;36:1304-11
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: Alcohol, Drug Abuse, and Mental Health Administration, Public Health Service, US Department of Health, Education, and Welfare 1976
   Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44
   PubMed Web of Science ®Google Scholar
• Arnold LM, Crofford LJ, Martin SA, et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007;8:633-8
   PubMed Web of Science ®Google Scholar
• Bennett RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005;53:519-27
   PubMed Web of Science ®Google Scholar
• Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45
   PubMed Web of Science ®Google Scholar
• Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18:13-9
   PubMedGoogle Scholar
• Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40
   PubMed Web of Science ®Google Scholar
• Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9
   PubMed Web of Science ®Google Scholar
• Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38:1211-7
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• Ginsberg F, Mancaux A, Joos E, et al. A randomized placebo-controlled trial of sustained release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain 1996;4:37-47
   Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
   PubMed Web of Science ®Google Scholar
• Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998;37:1279-86
   PubMedGoogle Scholar
• Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 2001;19:697-702
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
   PubMed Web of Science ®Google Scholar
• Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
   PubMed Web of Science ®Google Scholar
• Florian H, Young JP, Jr. Haig G. Efficacy and safety of pregabalin as long-term treatment of pain associated with fibromyalgia: a 1-year, open-label study [abstract]. Arthritis Rheum 2007;56(9 Suppl):S602
   Google Scholar
• Chappell AS, Littlejohn G, Kajdasz D, et al. A 1-yr safety and efficacy study of duloxetine in patients with fibromyalgia [abstract]. Ann Rheum Dis 2008;67(II Suppl):253
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Medicaid. Drug utilization data. Baltimore, MD: Centers for Medicare & Medicaid Services/US Department of Health & Human Services, 2010
   Google Scholar
• National drug code directory. Rockville, MD: US Food and Drug Administration/US Department of Health & Human Services, 2010
   Google Scholar
• Goldenberg D, Gerwin R, McNett M, et al. The economic burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey among working-age adults in the United States. J Manag Care Pharm 2011;9:71
   Google Scholar
• Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin 2010;26:965-75
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Paine J, et al. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149:360-4
   PubMedGoogle Scholar
• Gore M, Dukes E, Rowbotham D, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract 2006;6:265-72
   PubMedGoogle Scholar